Bruce Wallace brings a depth of expertise in GMP and the quality systems necessary for pharmaceutical production.
Helius Therapeutics has appointed Bruce Wallace as its chief quality officer.
His previous role was with contract medicines manufacturer, Argenta, where he was global head of quality, with responsibility for quality and Good manufacturing practices (GMP) compliance at the company’s US, UK, and New Zealand sites.
The executive appointment sees Wallace as a key part of the Helius leadership team, said Paul Manning, co-founder and chief executive of Helius Therapeutics.
“With a strong background in both human and animal health, [Bruce] brings extraordinary expertise in GMP and the quality systems necessary for pharmaceutical production,” Manning said.
Recently Helius announced it has raised a further $20 million from private investors, with the Kiwi-owned company achieving a market capitalisation of $105m. Well-placed to develop a new generation of novel medicinal cannabis products, the additional funding will also enable Helius to conduct the first clinical trials in New Zealand with Kiwi patients.
Wallace started his career in pharmaceutical manufacturing in the US in 1999 with the production of vaccines to prevent pneumonia in humans. He then moved to quality assurance, managing the safety and efficacy of vaccines as well as compliance with US and international GMP regulations. He was also part of a clinical quality group approving products to be used in human clinical trials.
Immigrating to New Zealand, he was appointed by Argenta in 2009. For more than a decade he had responsibility for managing the company’s quality systems and R&D compliance.
Wallace believes Helius’ state-of-the-art good manufacturing practice facility is ideally suited for developing and producing innovative medicinal cannabis products of the highest quality. The company’s East Tamaki site will oversee cannabis extraction, processing and packaging.
This is supplied content and not commissioned or paid for by NBR.
